ArticleBMC oral health2025
Endodontic therapy and Medication-related osteonecrosis of the jaw onset: a scoping review and expert opinion-based qualitative meta-synthesis.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Low awareness of medication-related osteonecrosis of the jaw among dentists: a systematic review with a medical and bioethical perspective.BMC medical ethics · 2026Pooled it
- Impact of denosumab therapy on periapical healing following root canal treatment: a 10-year retrospective case-control study.BMC oral health · 2026Article
- A scientometric study on research trends and characteristics of medication-related osteonecrosis of the jaw.Journal of dental sciences · 2026Article
- Oral health status and quality of life in female patients receiving low dose bone-modifying agents for cancer treatment-induced bone loss: a single-center exploratory study.Frontiers in oral health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedication-related osteonecrosis of the Jaw (MRONJ) is a serious side effect of bone-modifying agents (BMAs), including bisphosphonates, denosumab, and antiangiogenic drugs. Some dental procedures are recognized as local risk factors for MRONJ. Given the lack of specific guidelines for root canal therapy in patients treated with BMA, this scoping review aimed to investigate the risk of MRONJ associated with failed root canal therapy. Subsequently, a meta-synthesis of expert opinions was performed to identify existing recommendations and pitfalls of root canal therapy in patients at risk of MRONJ.
methodsA review search was conducted in PubMed, Scopus, and Web of Science to answer the PIO question: Is root canal therapy failure associated with an increased risk of developing MRONJ? Subsequently, a meta-synthesis was conducted to analyze guidelines, recommendations, and expert opinions regarding root canal therapy in BMA-treated patients.
resultsFive studies were included. All studies were case reports and case series, except one case-control study. Twenty-three patients who developed MRONJ after root canal therapy failure were analyzed. Also, a case- control study including 65 patients receiving BMAs and 46 patients never treated with BMAs was evaluated. In the last one only 4.8% of patients under BMAs developed MRONJ. The most common BMA used was zoledronate. A total of 223 teeth underwent root canal therapy.
conclusionsThis study highlights the potential risks of root canal therapy failure in BMA-treated patients, emphasizing the need to evaluate treatment appropriateness and risk-benefit ratio carefully.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.